Over the past 12 months, $CTMX has been discussed by 2 distinct FinTwit voices, generating 12 mentions between July 25, 2025 and March 16, 2026. Jacob Plieth (@jacobplieth) dominated the conversation with 11 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 1 mention. The biotech category accounted for all discussion of CytomX Therapeutics in this period. Most recent commentary from March 2026 focused on clinical efficacy trends and share performance, with Plieth noting that "$CTMX efficacy wanes, but varseta-M still looks good. Shares +64% now!" and separately discussing expectations around response rates, stating "it would have been unrealistic for ORR to remain near 30% $CTMX."